Scopus Biopharma Stock Return On Equity
SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus Biopharma fundamentals help investors to digest information that contributes to Scopus Biopharma's financial success or failures. It also enables traders to predict the movement of Scopus OTC Stock. The fundamental analysis module provides a way to measure Scopus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scopus Biopharma otc stock.
Scopus |
Scopus Biopharma OTC Stock Return On Equity Analysis
Scopus Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Scopus Biopharma Return On Equity | -15.6 |
Most of Scopus Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Scopus Biopharma has a Return On Equity of -15.596. This is 34.94% lower than that of the Healthcare sector and 57.22% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Scopus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in return on equity category among its peers.
Scopus Fundamentals
Return On Equity | -15.6 | ||||
Return On Asset | -4.61 | ||||
Current Valuation | 1.18 M | ||||
Shares Outstanding | 21.09 M | ||||
Shares Owned By Insiders | 50.66 % | ||||
Shares Owned By Institutions | 2.15 % | ||||
Number Of Shares Shorted | 23.77 K | ||||
Price To Book | 2.42 X | ||||
EBITDA | (26.18 M) | ||||
Net Income | (26.95 M) | ||||
Cash And Equivalents | 1.16 M | ||||
Cash Per Share | 0.05 X | ||||
Total Debt | 2.54 M | ||||
Debt To Equity | 0.61 % | ||||
Current Ratio | 0.31 X | ||||
Book Value Per Share | (0.26) X | ||||
Cash Flow From Operations | (11.42 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.51) X | ||||
Target Price | 12.0 | ||||
Beta | 1.16 | ||||
Market Capitalization | 2.17 M | ||||
Total Asset | 8.19 M | ||||
Z Score | -9.9 | ||||
Net Asset | 8.19 M |
About Scopus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scopus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scopus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scopus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |